In this episode, Colin Hayward, CMO of Telix- a commercial-stage biopharmaceutical company, talks about his contribution to the success of Rituximab which culminated in transforming it into a $3 billion radiopharmaceutical giant.

He also shares invaluable insights into the challenges of leadership, the burden of firing people, and the strategic decisions that drive success in the fast-paced world of biotech innovation.

Here's what you are in for:

01:36 Colin's Switch from Medicine to Biotech

04:15 Moving from Treating Patients to Business

05:58 Lessons from Working on Rituxan

10:59 Changing Careers: Consulting, CROs, and Teamwork

23:03 Tips on Hiring and Making a Strong Biotech Team

27:45 The burden of Firing people

About Colin Hayward

Colin Hayward, MD is the former Chief Medical Officer at Telix Pharmaceuticals, a company that specializes in radiopharmaceuticals. He has over 20 years of experience in the global pharmaceutical and biotech industries. Colin leads the medical, regulatory, clinical operations, and safety activities at Telix worldwide.

He originally wanted to play football professionally for Brighton Hove Albion, but realized he wasn't good enough at age 12. Switched to field hockey, was academically gifted, loved science, and decided to pursue medicine to help people and dive deeper into science.

About Charles

Charles Spence leads Discera, a leading recruitment firm specializing in the biopharma industry.

He graduated with a biomedical degree, has worked in hospitals (including translation work in Seoul, South Korea), and also spent years doing diabetes research. After doing research and travel, a career in business and science felt the most appropriate.

In 2023, Charles decided to launch his firm - Discera Search. A firm committed to solving the biggest talent needs of early clinical stage SME biotechs on the East Coast and DACH.

Connect with Charles:

LinkedIn: https://www.linkedin.com/in/charles-spence-clinical/

Website: https://www.discera-search.com/